Intravitreal Bevacizumab (Avastin) therapy for Proliferative Diabetic Retinopathy

Effects of Intravitreal Bevacizumab (Avastin) therapy on visual acuity in patients with Proliferative Diabetic Retinopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138903314232N1

Enrollment

Registered

2010-11-26

Start date

2007-10-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy. Retinal disorders in diseases classified elsewhere

Interventions

One intravitreal injection of 1.25 mg of bevacizumab (Avastin).

Treatment - Drugs

One intravitreal injection of 1.25 mg of bevacizumab (Avastin)

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients were not offered treatment if they had uncontrolled hypertension or recent myocardial infarction or cerebral vascular accident.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Visual Acuity. Timepoint: 0, 4, 12 weeks. Method of measurement: complete ophtalmic examination.	—

Secondary

Measure	Time frame
Speed of improvement and durability of visual acuity. Timepoint: 4 and 12 weeks after intervention. Method of measurement: ophtalmic examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEbrahim Mikaniki

Babol university of medical sciences

dr_emikaniki@yahoo.com+98 11 1219 9015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026